Repligen (NASDAQ:RGEN) Releases FY24 Earnings Guidance

Repligen (NASDAQ:RGEN) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $1.50-1.58 for the period, compared to the consensus earnings per share estimate of $1.44. The company issued revenue guidance of $630-639 million, compared to the consensus revenue estimate of $629.61 million. Repligen also updated its FY 2024 guidance to 1.500-1.580 EPS.

Repligen Stock Performance

Shares of RGEN stock opened at $139.51 on Tuesday. The company has a market capitalization of $7.81 billion, a price-to-earnings ratio of -3,487.75, a P/E/G ratio of 4.04 and a beta of 0.96. Repligen has a 1-year low of $113.50 and a 1-year high of $211.13. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. The stock’s fifty day simple moving average is $141.56 and its 200-day simple moving average is $145.05.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Wells Fargo & Company initiated coverage on shares of Repligen in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price target for the company. Benchmark reiterated a “hold” rating on shares of Repligen in a research report on Monday, August 5th. JPMorgan Chase & Co. lifted their target price on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 31st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $205.00 price target on shares of Repligen in a research note on Thursday, September 26th. Finally, Stephens reiterated an “overweight” rating and set a $170.00 price objective on shares of Repligen in a report on Tuesday, July 30th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Repligen has an average rating of “Moderate Buy” and an average target price of $190.25.

Insider Activity at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at $20,328,540.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 1.20% of the stock is owned by company insiders.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.